Dupilumab Phase 4 Study

Stopped early

Conditions studied: Atopic Dermatitis

In brief

The investigators will monitor for the incidence of adverse-events in a prospective, longitudinal, non-interventional and observational real-world sub-study of adults patients with moderate-to-severe AD who are receiving dupilumab as standard-of-care therapy.

Key facts

Study ID

NCT03411837

Run by

Northwestern University

People needed

46

Starts

2017-10-16

Expected to finish

2019-08-31

Last updated by the study team

2021-10-12

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Individuals aged 18 and over who have been diagnosed with Atopic Dermatitis and are using dupilumab therapy as part of standard of care.
• Parents of adolescents ages 12 to 17 who have been diagnosed with Atopic Dermatitis and are receiving dupilumab off-label for the management of AD.

You may not qualify if…

• Patients not on dupilumab
• Those who do not comply with the study requirements
• Those who do not provide informed consent

Where it is running

• Northwestern University Department of Dermatology — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.